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INTRODUCTION                                                               
Marfan syndrome is the most common inherited multisystem disorder of 
connective tissue. This autosomal dominant condition has a reported 
incidence of 2-3 per 10,000 individuals without gender, racial, or ethnic 
predilection. Early identifi cation and appropriate management improves 
the prognosis of patients with Marfan syndrome who are prone to life-
threatening cardiovascular complications. 
GENETICS                                                                            
Marfan syndrome is caused by a mutation of the fi brillin-1 gene located on 
chromosome 15. (1)  Fibrillin-1 protein is an extracellular matrix glycoprotein, 
which is an important component of the connective tissue elastic microfi brils 
and is essential to normal fi brinogenesis. Fragmentation and disorganization 
of the elastic fi bers in the aortic media is a histological marker of Marfan 
syndrome, so-called medial degeneration. Those histological changes make 
the aorta stiffer and less distensible than the normal aorta. More recently, 
endothelial dysfunction has also been demonstrated in the Marfan aorta. 
The penetrance of the fi brillin mutation is high and the phenotypic 
expression is variable. To date, more than 500 different mutations involving 
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the fi brillin-1 gene have been identifi ed, but no correlation between the 
specifi c type of fi brillin-1 mutation and the clinical phenotype has been 
recognized. (2,3) In approximately 75% of cases, an individual inherits the 
disorder from an affected parent. The remaining 25% of cases result from 
de novo mutation. There is little prognostic information provided by the 
detection of a mutation beyond the available information provided from 
the patient’s own family history.  Therefore, genetic testing is mainly used for 
adjunctive clinical diagnosis in selected cases. 
Approximately 10% of mutations that cause classic Marfan syndrome are 
missed by conventional screening methods. Limitations to genetic testing 
include:
1.  The mutation in fi brillin-1 gene can cause conditions other than Marfan-
like disorder. 
2.  None of the current methods used to fi nd mutations in fi brillin-1 gene 
identify all mutations that cause Marfan syndrome. 
3.  Family members with the same mutation causing Marfan syndrome can 
show wide variation in clinical manifestations.
The diagnosis of Marfan syndrome depends primarily on clinical features 
which have been codifi ed into the Ghent diagnostic nosology (Table 1). (4) 
DIAGNOSIS                                                                         
The diagnosis of Marfan syndrome requires a careful history, including 
information about any family members who may have the disorder or had 
unexplained early or sudden death. The goal is to determine whether the 
diagnosis can be established clinically. The modifi ed Ghent criteria, proposed 
in 1996, allow a uniform approach to the diagnosis of Marfan syndrome. (4) 
A comprehensive multidisciplinary approach involving cardiac, orthopedic, 
ophthalmologic, as well as genetic consultations and testing are warranted 
in order to confi rm or exclude the diagnosis. In the absence of any family 
history of Marfan syndrome, the diagnosis is made by identifying major 
criteria in two different organ systems and involvement of a third system or 
in the presence of fi brillin-1 mutation and major criteria in one system and 
involvement in a second organ system (Table 1).  In the presence of a family 
history of Marfan syndrome in a fi rst-degree relative who meets major 
criteria independently, the diagnosis of Marfan syndrome can be made in 
the presence of one major criterion in one organ system and involvement 
of a second organ system.  
Cardiovascular manifestations
The importance of the cardiovascular involvement from Marfan syndrome 
was initially outlined by McKusick et al. (5) Cardiovascular complications are 
now recognized to be the major cause of morbidity and mortality in 
patients with Marfan syndrome. Thus it is important to consider the 
diagnosis and perform cardiovascular imaging studies in all patients with 
possible Marfan syndrome, and serial imaging in all patients with confi rmed 
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 Marfan syndrome is the most common inherited 
multisystem disorder of connective tissue. This autosomal dominant 
condition has an incidence of 2-3 per 10,000 individuals. Although 
genetic diagnostic techniques are available, the diagnosis is primarily 
made using the ghent diagnostic criteria. Early identifi cation and 
appropriate management improves the prognosis of patients with 
Marfan syndrome who are prone to the life-threatening cardiovascular 
complications of aortic dissection and rupture. Beta-blockers have been 
demonstrated to slow aortic growth and thus delay the time to aortic 
surgery. Operative intervention has markedly changed the prognosis of 
patients with marfan syndrome and can be safely performed on an 
elective basis.
The advance in the understanding of the cause of marfan syndrome, as 
well as early recognition of the disorder and subsequent institution of 
medical and surgical therapy has resulted in dramatic improvement in 





Table 1. Summary of the major and minor suggested Ghent criteria used to estabish the diagnosis of Marfan syndrome.
Skeletal Major (at least four of the following constitutes a major criterion) Minor 
Pectus carinatum Pectus excavatum
Pectus excavatum requiring surgery Joint hypermobility
Reduced upper to lower segment ratio OR arm span to height ratio >1.05 Highly arched palate with crowding of teeth
Wrist and thumb signs Facial appearance: dolichocephaly (long narrow skull) 
Scoliosis of >20° or spondylolisthesis  malar hypoplasia ( fl attening)
Reduced extension at the elbows (<170°)  enophthalmos ( sunken eyes)
Medial displacement of the medial malleolus causing pes planus  retrognathia ( recessed lower mandible)
Protrusio acetabuli of any degree   down-slanting palpebral fi ssures
For involvement of the skeletal system, at least two features contributing to major criteria, or one major and two minor criteria must be present.
 
Ocular Major Minor
Ectopia lentis Flat cornea
 Increased axial length of globe (<23.5 mm)
 Hypoplastic iris OR hypoplastic ciliary muscle causing decreased miosis
   For involvement of the ocular system, at least two of the minor criteria must be present.
Cardiovascular Major (either of the following constitutes a major criterion) Minor
Dilatation of the ascending aorta with or without aortic regurgitation and  Mitral valve prolapse with or without mitral valve regurgitation
involving at least the sinuses of Valsalva Dilatation of the main pulmonary artery, in the absence of valvular or  
Dissection of the ascending aorta peripheral pulmonic stenosis below the age of 40 years
 Calcifi cation of the mitral annulus below the age of 40 years
 Dilatation or dissection of the descending thoracic or abdominal aorta  
 below the age of 50 years
For involvement of the cardiovascular system, only one of the minor criteria must be present.
Pulmonary System Major Minor
 None Spontaneous pneumothorax
  Apical blebs
 For involvement of the pulmonary system, only one of the minor criteria must be present.
Skin and Integument Major Minor
 None Striae atrophicae (stretch marks) not related to marked weight gain,  
  pregnancy or repetitive stress
  Recurrent or incisional herniae
 For involvement of the skin and integument, only one of the minor criteria must be present.
Dura Major Minor
 Lumbosacral dural ectasia by CT or MRI None
Family/Genetic History Major (one of the following constitutes a major criterion) Minor
 First-degree relative who independently meets the diagnostic criterion:  None
 Presence of mutation in FBN1
 Presence of a haplotype around FBN1 inherited by descent and unequivocally 







The cardiovascular manifestations of Marfan syndrome include:
1. Dilatation of the ascending aorta, characteristically at the sinuses of 
Valsalva with associated increased risk of aortic valve regurgitation, as 
well as aortic dissection (Fig. 1). 
2.  Mitral valve prolapse with or without mitral valve regurgitation.
3.  Mitral anular calcifi cation noted in patients younger than age 40 years.
4.  Pulmonary artery dilatation in the absence of pulmonary valve stenosis.
5.  Dilatation or dissection of the descending thoracic aorta in a patient 
younger than age 50 years (Fig. 2).
 
Aortic sinus enlargement leading to aortic aneurysm is progressive and is 
present in 50% to 60% of adults and in 50% of children with Marfan 
syndrome and can be readily detected by echocardiography (Fig. 3). 
Recent data suggest that Marfan syndrome is present in 50% of aortic 
dissection patients presenting under age 40 years and accounts for only 2% 
of dissections in older patients. (6) (7)  
Risk factors for aortic dissection in Marfan syndrome include:
1. aortic diameter of more than 5 centimeters, 
2. aortic dilatation extending beyond the sinuses of Valsalva, 
3. rapid rate of aortic dilatation (more than 5% per year or more than 
2 millimeters per year in adults), and 
4.  family history of aortic dissection.
FIGURE 1:  Pathology specimen demonstrating heart and aorta following fatal aortic 
dissection. The red arrow shows the external aortic tear into the pericardial sac. The 
dissection channel is large and ﬁ lled with clotted blood. The true lumen has been narrowed 
substantially. (Courtesy of Dr. William D. Edwards, Department of Laboratory Medicine and 
Pathology, Mayo Clinic College of Medicine.)
FIGURE 2:  Descending aortic dissection demonstrated on magnetic resonance imaging 
of the chest with gadolinium. The dissection starts distal to the left subclavian artery and 
extends to the aortic bifurcation.
FIGURE 3:  Two-dimensional echocardiogram, parasternal long axis image, demonstrates 
dilatation of the ascending aorta at the level of the aortic sinuses. The leading edge to 
leading edge method is used for ascending aortic measurement.
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Aortic diameter should be measured by transthoracic echocardiogram at 
multiple levels and related to normal values based on age and body surface 
area reported by Roman and Devereux (Fig. 4). (8)  The maximum aortic 
dimension in Marfan syndrome is usually located at the sinuses of Valsalva.  
Mitral valve prolapse with or without mitral valve regurgitation can be 
seen in 60% to 80% of patients with Marfan syndrome undergoing an 
echocardiographic examination. However, only an estimated 25% of Marfan 
patients with mitral valve prolapse have progressive mitral valve regurgitation 
that requires operative intervention. Tricuspid valve prolapse with and 
without regurgitation also occurs in Marfan syndrome.
Skeletal manifestations
The most common skeletal manifestations of Marfan syndrome can be 
easily assessed by a full skeletal examination that includes measurements of 
height, arm span to height ratio, upper to lower segment ratio, and hand 
and foot examinations, as well as evaluation for scoliosis, pectus deformity, 
high arched palate, medial rotation of the medial malleolus causing pes 
planus (fl at feet), joint hypermobility, reduced elbow extension, and 
arachnodactyly.
Occasionally hip x-ray and lumbosacral MRI or CT may be helpful to 
document the presence of protrusio acetabula or dural ectasia respectively. 
Imaging studies are usually performed for symptoms or occasionally when 
these fi ndings are required to fulfi ll the Ghent diagnostic criteria for the 
Marfan syndrome.
Ocular manifestations
Lens dislocation is the only ocular manifestation that is considered a major 
criterion and is present in 60% of patients with Marfan syndrome. This is 
best assessed with a slit-lamp examination with pupillary dilatation 
performed by an ophthalmologist. Lens dislocation usually occurs early in 
life but annual ophthalmologic evaluation is recommended due to the 
recognized risk of early severe myopia, retinal detachment, glaucoma, and 
cataract formation in Marfan patients. The other manifestations of Marfan 
syndrome are summarized in Table 1.
 
Children with suspected Marfan syndrome who do not meet the Ghent 
diagnostic criteria should have repeat evaluation in preschool, before puberty, 
and at age 18, since some of the clinical manifestations of Marfan syndrome 
become evident with age. Serial aortic imaging follow-up is recommended 
when the aorta is enlarged, irrespective of diagnostic criteria. 
 
Differential diagnosis
The differential diagnosis of Marfan syndrome includes:
1. Homocystinuria which shares several skeletal and ocular features of 
Marfan syndrome, in addition to mitral valve prolapse. Homocystinuria 
is an autosomal recessive disorder that is characterized by an elevated 
urinary homocysteine excretion and can be diagnosed by measuring 
total homocysteine.
2. MASS phenotype includes mitral valve prolapse, aortic enlargement, 
and nonspecifi c skin and skeletal features.
3. Ehlers-Danlos syndrome type IV includes skin laxity, scars, and easy 
bruising and a propensity toward arterial dilatation and dissection.
FIGURE 4: 95% normal  conﬁ dence limits for aortic root diameter at the sinuses of Valsalva in relation to body surface area as described by Roman et al for three age groups














y = 102 + 0.98 x  l  SEE = 0.18
r = 0.93  l  P < 0.0005
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y = 97 + 1.12 x  l  SEE = 0.24
r = 0.71  l  P < 0.0005


























y = 1.97 + 0.74 x  l  SEE = 0.37
r = 0.40  l  P < 0.0005
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Reprinted from Am J Cardiol, 64:507-12. Roman MJ, Devereux RB, Kramer-Fox R, O’Loughlin J (1989), with permission from Elsevier.
4. Stickler syndrome where retinal detachment and not ectopia lentis is a 
common feature, additional features include cleft palate and hearing 
loss.
5. Congenital contractural arachnodactyly or Beals syndrome is an 
autosomal-dominant disorder manifest by joint contractures, scoliosis, 
and crumpled ear malformation in addition to a marfanoid 
appearance.
6. Familial thoracic aortic aneurysm or aortopathy. These individuals do 
not show any other systemic manifestation of Marfan syndrome but 
have familial tendency to arterial dilatation and dissection.
7. Congenital bicuspid aortic valve disease with associated aortopathy, 
where the dilatation of the ascending aorta is often in its mid-section 
rather then at the aortic sinuses. The bicuspid aortic valve may function 
normally.
8. Loeys-Dietz syndrome, which includes hypertelorism and the presence 
of a broad or bifi d uvula, in addition to vascular involvement characterized 
by arterial tortuosity and aneurysms with an increased risk of dissection 
throughout the arterial tree, often at small arterial sizes (9).
MEDICAL MANAGEMENT                                               
The management of patients with Marfan syndrome should involve a 
multidisciplinary approach and treatment should be tailored to individual 
manifestations. Early diagnosis and treatment are benefi cial. Marfan patients 
of all ages should undergo at least annual evaluation with clinical history, 
examination, and echocardiogram or another aortic imaging study. Genetic 
counseling should be provided initially to aid in the diagnosis and should 
also be provided to potential parents. Phenotypic variability, pregnancy 
counseling, and the availability of prenatal and presymptomatic diagnostic 
testing should be discussed. (10)  
The histologic abnormalities noted in the Marfan aorta reduce its 
distensibility and compliance; as a result, the aorta becomes stiffer and 
demonstrates excessive dilation with age. Since beta blockade can increase 
aortic distensibility and reduce aortic stiffness, in addition to lowering the 
heart rate and left ventricular ejection force, these medications have been 
the treatment of choice and should be considered in all patients with 
Marfan syndrome. A randomized trial of propranolol treatment in 
adolescents and young adults with Marfan syndrome has demonstrated a 
reduced rate of aortic dilatation and fewer aortic complications in the 
treatment group. (11)  A total of 70 patients with Marfan syndrome were 
treated with propranolol, mean dose to 112 milligrams a day. At an average 
follow-up of ten years, the mean slope of regression line for aortic root 
dimensions was signifi cantly lower in the propranolol group compared to 
the control group. In another study involving 44 patients with Marfan 
syndrome followed up for almost four years, those who were taking a beta 
blocker or calcium channel blocker if intolerant to beta blocker, showed a 
slower absolute aortic growth rate of 0.9 vs. 1.8 mm/year after adjustment 
for age and body size. (12) Those who responded to beta blockade tended 
to have a smaller aortic diameter (less than 4.0 centimeters) suggesting that 
a reduction in the rate of aortic dilatation with beta blockade is greatest in 
young patients with a small aorta. Therefore, beta blockade should be 
considered in all patients with Marfan syndrome, including children, and 
those with aortic root diameter of less than 4 cm, unless contraindicated. 
The beta-blocker dose should be adjusted to maintain a resting heart rate 
of 60-70 beats per minute or heart rate of 100 beats per minute after 
submaximal exercise. 
Recent data demonstrated dramatic alteration in vascular abnormalities in 
the aortas of Marfan mice treated with angiotensin converting enzyme 
inhibitor. (13) A multicenter prospective comparison of beta blocker and 
angiotensin receptor blocker is planned in young, unoperated Marfan 
patients. Until data support therapy in humans, angiotensin receptor blocker 
therapy should be considered second line after beta blocker, but should be 
considered in patients with hypertension or beta blocker intolerance. In the 
presence of aortic or mitral regurgitation, endocarditis prophylaxis is 
recommended. 
One of the major concerns in Marfan syndrome is the increased risk of 
aortic dissection, which is inherent to the histologic abnormalities of the 
Marfan aorta. Patients with Marfan syndrome should be counseled to seek 
urgent medical evaluation for any acute chest, back, or abdominal pain, 
syncope, sudden change in vision or sense of impending doom.
Treatment with beta blockers, though benefi cial in most Marfan patients, 
does not protect against aortic dissection. In one study, 20% of patients 
with Marfan syndrome treated with beta blockers or calcium channel 
blockers had major cardiovascular complications requiring surgery over a 
four-year period. (12) Patients should also be educated to avoid smoking and 
monitor their blood pressure due to the recognized vascular complications 
related to nicotine use and hypertension. The goal blood pressure per 
JNC-7  (14) is less than 120/80 mm Hg.
Patients with Marfan syndrome should avoid isometric exercise, competitive 
and contact sports, or exercising to the point of exhaustion. (15) As a general 
principle, participation in recreational exercise categorized as low to 
moderate intensity is appropriate for patients with Marfan syndrome, unless 
they have had prior aortic root and/or valve replacement. Weight lifting, 
body building, and competitive sports such as ice hockey, full-court basketball, 
surfi ng, and scuba diving should be avoided. Impact sports may also cause 
ocular complications in patients with Marfan syndrome. For other activities 
thought to be of intermediate risk, such as singles tennis, soccer, touch 
football, baseball and skiing, individual assessment is suggested. (16)
Serial aortic imaging is critical in the management of all patients with Marfan 
syndrome. It is suggested that the aortic root diameter be plotted serially 
against body surface area. (8) In adults, a yearly echocardiogram measurement 
of the aortic root diameter is recommended, as long as the diameter is less 
than 4.5 cm and no major change in aortic dimension has been noted 







root diameter is more than 4.5 cm, or the patient has not had prior 
documented aortic enlargement. Alternatively, CT or MRI of the chest 
could be performed. These imaging techniques provide a complete 
assessment of the thoracic aorta, including the descending segment that 
might not be optimally visualized by echocardiography. These imaging 
modalities complement each other. Periodic CT or MR imaging of the 
descending thoracic and abdominal aorta is recommended in all patients 
with Marfan syndrome, especially prior to aortic root replacement, due to 
the recognized risk of aneurysm formation in other parts of the aorta. 
Annual ophthalmologic examination, including screening and treatment for 
myopia, retinal detachment, glaucoma, and cataracts, is recommended for 
all patients with Marfan syndrome. 
SURGICAL MANAGEMENT                                             
There is general agreement, based on a number of comparative studies, 
that overall outcome is better in Marfan patients treated with early aortic 
root surgery, in addition to continuing beta blockade. (17,18)  Prophylactic 
surgery is recommended when the diameter of the aortic sinuses of 
Valsalva reaches 5.0 cm. (19) Other factors such as family history of aortic 
dissection, severe aortic valve regurgitation with associated symptoms or 
progressive ventricular dilatation or dysfunction, the possibility of a valve-
sparing operation, and the rate of aortic dilatation (aortic root growth >2 
mm/yr), may indicate the need for surgery at a smaller aortic sinus 
dimension. An increase in aortic dimension of more than 1.0 centimeter 
per year is regarded as rapid progression in a child, whereas in the adult an 
increase of ≥5% per year or an increase of more than 2 mm per year is 
considered signifi cant, emphasizing the need for regular aortic root 
surveillance.  
The original operation developed for Marfan patients was the Bentall 
composite graft. This includes aortic root and valve replacement with either 
a biological or mechanical valve and requires coronary artery reimplantation 
(Fig. 5). The composite aortic graft is associated with a low operative 
mortality, especially when done electively, and a 5-, 10-, and 20-year survival 
of 88%, 81%, and 75%, respectively.  The Bentall procedure is the operation 
of choice in patients with severe aortic valve regurgitation and is often 
preferred in the setting of emergent operation for aortic dissection.
In the absence of important aortic valve regurgitation, a valve-sparing aortic 
root replacement can be considered (Fig. 6).  The degree of the aortic valve 
regurgitation, due to root dilatation, is a major determinant of the kind of 
surgical intervention offered when aortic root replacement is required. 
There are various types of valve-sparing operation. The mortality risk of the 
valve-sparing operations is low with a 5-yr survival rate of 96±3%. Mild or 
no aortic regurgitation may be present in up to 75% of patients, for as long 
as 10 years. The risk of requiring aortic valve replacement for severe aortic 
valve regurgitation is estimated to be 10% at ten years. Aortic valve-sparing 
operation is an indication for early surgery and therefore an aortic root 
diameter of <50 millimeters with preserved aortic valve function is an 
indication to consider surgical repair. In addition, the valve-sparing operation 
or the use of a biological prosthesis is recommended for a woman who 
FIGURE 5:  Schematic of the Bentall operation. In this procedure the proximal aorta is 
replaced with a valved conduit, the coronary arteries are reimplanted. This schematic 
demonstrates a mechanical prosthesis. Biological prostheses can also be used.
FIGURE 6:  Schematic of the valve sparing aortic root replacement. The ascending aorta 
is replaced with a graft, the native aortic valve is preserved, and the coronary arteries are 
reimplanted. 
wishes to become pregnant and for other patients with relative 
contraindication for long-term anticoagulation. (20)
 
Mitral valve repair for severe mitral regurgitation with associated symptoms 
or progressive left ventricular dilatation or dysfunction carries a very low 
operative risk (<1%). (21) 
POSTOPERATIVE CARDIOVASCULAR CARE             
Marfan patients require long-term medical treatment and lifelong 
surveillance, even after aortic root surgery, representing a major 
commitment for patient and doctor. Beta blockers should be continued 
indefi nitely unless not tolerated. Long-term aspirin and endocarditis 
prophylaxis are recommended in all patients. Long-term anticoagulation 
with warfarin is recommended for patients with mechanical prostheses 
or in presence of atrial fi brillation. At least annual cardiovascular and 
ophthalmologic evaluation with a clinical history, examination, and 
transthoracic echocardiogram is recommended with periodic imaging of 
the descending thoracic and abdominal aorta. As Marfan patients age, 
reoperation is often needed if they develop vascular complications 
elsewhere in the arterial system, reemphasizing the importance of 
continuing beta-blocker therapy. Mitral valve replacement or repair may be 
required in up to 10% of those requiring aortic root surgeries. As a group, 
it is believed that more than 60% of patients with Marfan syndrome require 
multiple operations during their lifetime and therefore lifelong comprehensive 
multidisciplinary follow-up is recommended. 
 
Periodic imaging of the entire aorta is recommended indefi nitely following 
initial aortic repair and monitoring can be accomplished with MRI or CT 
angiography. The rate of change of the aortic diameter should infl uence 
follow-up intervals. 
Indications for replacement of an enlarged segment of the aorta should 
include:
1. Rapid increase in aortic size of more than 5 to 10 millimeters per year, 
2.  Ascending aortic diameter of >50 millimeters,
3. Affected segment diameter twofold greater than the adjacent segment, 
or 
4.  Symptoms related to aortic dilatation.
An uncommon late complication of both composite and valve-sparing 
operation is the development of coronary ostial aneurysms. These 
aneurysms develop at the site of reimplantation as a result of the 
perioperative stretch of the weakened wall of the coronary ostium. 
PREGNANCY IN MARFAN SYNDROME                       
Pregnancy in Marfan syndrome is possible. There are, however, two major 
issues that need to be discussed with the patient and family, including the 






of transmission of Marfan syndrome to the fetus. Due to the autosomal 
dominant nature of the disorder, each offspring of an affected Marfan 
parent has a 50% chance of inheriting the genetic mutation. Genetic 
counseling should be offered to all patients with Marfan syndrome. Mutation 
detection or linkage can be used for prenatal diagnosis if the parents wish. 
The risk of aortic dissection in pregnancy is increased and may be caused 
by the inhibition of collagen and elastin deposition in the aorta by estrogen 
and the hyperdynamic hypervolemic circulatory state of pregnancy. Previous 
reports of pregnancies involving patients with Marfan syndrome have 
demonstrated a complication rate of approximately 11%, mostly related to 
aortic rupture and endocarditis. The overall risk of death during pregnancy 
is around 1%. The risk of aortic root complication is increased when the 
aortic root diameter is more than 4 centimeters at the start of pregnancy 
and the risk is further increased when the aorta dilates rapidly during 
pregnancy. (22)  The risk of further dilatation of the aorta during pregnancy is 
lowest in the fi rst trimester and greatest in the third trimester, as well as 
during labor and in the fi rst few weeks post partum. In those who become 
pregnant, beta blocker therapy should be continued throughout pregnancy 
and patients should have serial follow-up echocardiograms to assess the 
change in the size of the aorta during pregnancy. Surgery should be 
considered during pregnancy in patients with progressive aortic dilatation 
or before the aortic root diameter reaches 55 millimeters. A planned 
cesarean delivery is generally the preferred mode of delivery in patients 
with the Marfan syndrome and enlargement. Assisted vaginal delivery can 
be considered when the aortic root diameter is less than 4 centimeters, the 
aorta has not demonstrated change during pregnancy, and there is no 
associated severe cardiovascular disease. Antibiotic prophylaxis administered 
around the time of delivery is appropriate for those patients with signifi cant 
valvular regurgitation or prior root and valve replacement surgery. 
Postpartum uterine hemorrhage should be anticipated as a complication of 
Marfan syndrome and has been reported in nearly 40% of women. (23) 
PROGNOSIS                                                                        
The life expectancy of untreated patients with Marfan syndrome is 
signifi cantly reduced, with an early study reporting the lifespan to be about 
32 years. However, with beta blocker therapy and elective surgical repair, 
the median cumulative probability of survival has increased gradually to 
72 years. (24) 
SUMMARY                                                                            
A marked advance in the understanding of the cause of Marfan syndrome, 
as well as early recognition of the disorder and subsequent institution of 
medical and surgical therapy, has resulted in dramatic improvement in the 
prognosis of this patient population over the past few decades. We 
anticipate that further medical advances, focused primarily on the genetic 
basis of Marfan syndrome, will allow continued therapeutic improvements 
with associated prognostic implications in years to come.
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